About Repligen (NASDAQ:RGEN)
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Industry, Sector and Symbol
Trailing P/E Ratio50.0704225352113
Forward P/E Ratio50.79
Sales & Book Value
Annual Sales$141.24 million
Price / Sales10.97
Cash Flow$0.84 per share
Price / Cash42.49
Book Value$13.58 per share
Price / Book2.62
Net Income$28.35 million
Return on Equity7.08%
Return on Assets5.23%
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) announced its earnings results on Thursday, February, 22nd. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks' consensus estimate of $0.12 by $0.08. The biotechnology company earned $41.60 million during the quarter, compared to analysts' expectations of $41.13 million. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The firm's revenue was up 62.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.08 earnings per share. View Repligen's Earnings History.
When will Repligen make its next earnings announcement?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of $0.68-0.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.72. The company issued revenue guidance of $180-186 million, compared to the consensus revenue estimate of $184.19 million.
Where is Repligen's stock going? Where will Repligen's stock price be in 2018?
7 Wall Street analysts have issued 12 month price targets for Repligen's stock. Their forecasts range from $40.00 to $50.00. On average, they expect Repligen's stock price to reach $44.57 in the next year. View Analyst Ratings for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Clovis Oncology (CLVS), Halozyme Therapeutics (HALO), Evotec (EVTCY), Puma Biotechnology (PBYI), China Biologic Products (CBPO), Amicus Therapeutics (FOLD), AnaptysBio (ANAB), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), arGEN-X BV (ARGX), Immunomedics (IMMU), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Horizon Pharma (HZNP), The Medicines (MDCO), Crispr Therapeutics (CRSP) and Akorn (AKRX).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Karen A. Dawes, Independent Chairperson of the Board (Age 64)
- Tony John Hunt, President, Chief Executive Officer, Director (Age 53)
- Jon K. Snodgres, Chief Financial Officer (Age 51)
- Nicolas M. Barthelemy, Independent Director (Age 51)
- Glenn L. Cooper M.D., Independent Director (Age 64)
- John G. Cox, Independent Director (Age 54)
- Glenn P. Muir, Independent Director (Age 58)
- Thomas F. Ryan Jr., Independent Director (Age 75)
Has Repligen been receiving favorable news coverage?
News coverage about RGEN stock has been trending positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repligen earned a news impact score of 0.39 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Repligen's major shareholders?
Repligen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.31%), TimesSquare Capital Management LLC (5.76%), William Blair Investment Management LLC (4.14%), OppenheimerFunds Inc. (3.86%), Conestoga Capital Advisors LLC (3.83%) and Mackenzie Financial Corp (2.16%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which major investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Gotham Asset Management LLC, Cortina Asset Management LLC, OppenheimerFunds Inc., Royce & Associates LP, Allianz Asset Management GmbH, Ranger Investment Management L.P. and First Trust Advisors LP. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which major investors are buying Repligen stock?
RGEN stock was purchased by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, William Blair Investment Management LLC, Wells Fargo & Company MN, Conestoga Capital Advisors LLC, TimesSquare Capital Management LLC, Macquarie Group Ltd., Goldman Sachs Group Inc. and North Star Asset Management Inc.. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $35.55.
How big of a company is Repligen?
Repligen has a market capitalization of $1.60 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.71 on an earnings per share basis. Repligen employs 476 workers across the globe.
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (RGEN)MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Repligen (NASDAQ:RGEN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.86||2.86||2.86||2.50|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$44.57||$44.57||$44.57||$41.00|
|Price Target Upside: ||25.38% upside||28.89% upside||28.89% upside||4.67% downside|
Repligen (NASDAQ:RGEN) Consensus Price Target History
Repligen (NASDAQ:RGEN) Analyst Ratings History
(Data available from 3/21/2016 forward)
Repligen (NASDAQ:RGEN) Earnings History and Estimates Chart
Repligen (NASDAQ RGEN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/22/2018||Q4 2017||$0.12||$0.20||$41.13 million||$41.60 million||View||N/A|
|11/9/2017||Q3 2017||$0.11||$0.15||$35.69 million||$36.58 million||View||N/A|
|8/3/2017||Q2 2017||$0.15||$0.20||$31.72 million||$32.40 million||View||Listen|
|5/4/2017||3/31/2017||$0.13||$0.15||$29.28 million||$30.59 million||View||Listen|
|2/22/2017||Q416||$0.07||$0.08||$24.05 million||$25.60 million||View||Listen|
|11/3/2016||Q316||$0.08||$0.08||$24.39 million||$24.70 million||View||N/A|
|8/4/2016||Q216||$0.13||$0.16||$24.75 million||$29.20 million||View||N/A|
|5/5/2016||Q116||$0.10||$0.12||$22.54 million||$25.10 million||View||N/A|
|2/25/2016||Q415||$0.07||$0.07||$19.84 million||$21.40 million||View||Listen|
|11/5/2015||Q315||$0.08||$0.08||$20.50 million||$19.80 million||View||N/A|
|8/6/2015||Q215||$0.08||$0.11||$20.05 million||$21.50 million||View||N/A|
|5/7/2015||Q115||$0.07||$0.09||$18.20 million||$20.82 million||View||N/A|
|3/13/2015||Q414||$0.04||($0.01)||$14.70 million||$15.40 million||View||N/A|
|11/6/2014||Q314||$0.04||$0.04||$15.60 million||$15.30 million||View||N/A|
|8/11/2014||Q114||$0.06||$0.09||$14.90 million||$15.60 million||View||N/A|
|5/8/2014||Q1||$0.07||$0.13||$15.14 million||$16.33 million||View||Listen|
|3/6/2014||Q413||$0.14||$0.10||$15.88 million||$10.40 million||View||Listen|
|11/7/2013||Q313||$0.13||$0.18||$16.27 million||$18.80 million||View||Listen|
|8/1/2013||Q2 2013||$0.10||$0.14||$15.97 million||$17.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.07||$12.82 million||$16.46 million||View||Listen|
|11/8/2012||Q312||$0.06||$8.63 million||$15.10 million||View||N/A|
Repligen (NASDAQ:RGEN) Earnings Estimates
2018 EPS Consensus Estimate: $0.71
2019 EPS Consensus Estimate: $0.82
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Repligen (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Repligen (NASDAQ RGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 87.61%
Repligen (NASDAQ RGEN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/8/2018||Thomas F Ryan Jr||Director||Sell||4,696||$36.16||$169,807.36||9,700|| |
|1/22/2018||Anthony Hunt||CEO||Sell||8,970||$35.95||$322,471.50||83,613|| |
|12/14/2017||Howard Benjamin||VP||Sell||12,729||$35.34||$449,842.86||36,554|| |
|3/21/2017||Karen A Dawes||Director||Sell||2,521||$34.12||$86,016.52||95,764|| |
|3/20/2017||Howard Benjamin||VP||Sell||12,216||$34.62||$422,917.92||36,124|| |
|3/20/2017||Thomas F Ryan Jr||Director||Sell||4,000||$34.83||$139,320.00||12,594|| |
|3/17/2017||Jon Snodgres||CFO||Sell||1,909||$34.91||$66,643.19||23,789|| |
|11/28/2016||Anthony Hunt||CEO||Sell||5,000||$33.12||$165,600.00||68,342|| |
|9/14/2016||Thomas F Ryan Jr||Director||Sell||2,700||$32.58||$87,966.00||9,394|| |
|6/30/2016||Thomas F Ryan Jr||Director||Sell||5,000||$26.60||$133,000.00||12,094|| |
|6/28/2016||Thomas F Ryan Jr||Director||Sell||10,000||$24.59||$245,900.00||27,094|| |
|5/11/2016||Howard Benjamin||VP||Sell||2,889||$26.72||$77,194.08||18,626|| |
|6/9/2015||Howard Benjamin||VP||Sell||35,000||$38.14||$1,334,900.00|| |
|5/11/2015||Walter C Herlihy||CEO||Sell||104,569||$37.94||$3,967,347.86|| |
|5/8/2015||Thomas F Ryan Jr||Director||Sell||20,000||$37.19||$743,800.00|| |
|3/23/2015||Walter C Herlihy||CEO||Sell||24,536||$31.78||$779,754.08|| |
|3/19/2015||James R Rusche||SVP||Sell||14,650||$33.30||$487,845.00|| |
|3/19/2015||Thomas F Ryan Jr||Director||Sell||10,000||$32.62||$326,200.00|| |
|3/19/2015||Walter C Herlihy||CEO||Sell||49,695||$33.08||$1,643,910.60|| |
|3/18/2015||Howard Benjamin||VP||Sell||15,795||$32.63||$515,390.85|| |
|11/19/2014||Walter C Herlihy||CEO||Sell||51,386||$23.43||$1,203,973.98|| |
|11/13/2014||Thomas F Ryan Jr||Director||Sell||10,000||$23.81||$238,100.00|| |
|11/11/2014||Howard Benjamin||VP||Sell||30,000||$23.56||$706,800.00|| |
|11/10/2014||Michael A Griffith||Director||Sell||23,342||$22.90||$534,531.80|| |
|8/13/2014||Howard Benjamin||VP||Sell||40,000||$20.34||$813,600.00|| |
|6/27/2014||Thomas F Ryan Jr||Director||Sell||10,000||$22.41||$224,100.00|| |
|6/24/2014||Thomas F Ryan Jr||Director||Sell||10,000||$21.78||$217,800.00|| |
|6/11/2014||Walter C Herlihy||CEO||Sell||60,335||$20.11||$1,213,336.85|| |
|6/9/2014||James R Rusche||SVP||Sell||30,000||$20.19||$605,700.00|| |
|6/6/2014||Daniel P Witt||SVP||Sell||47,709||$20.56||$980,897.04|| |
|4/15/2014||Daniel P Witt||SVP||Buy||10,000||$3.05||$30,500.00|| |
|8/8/2013||James R Rusche||SVP||Sell||30,000||$10.01||$300,300.00|| |
|6/21/2013||Karen A Dawes||Director||Buy||1,000||$7.70||$7,700.00|| |
|5/17/2013||Thomas F Ryan Jr||Director||Sell||21,000||$8.97||$188,370.00|| |
|5/15/2013||Thomas F Ryan Jr||Director||Sell||86,039||$9.01||$775,211.39|| |
|5/15/2013||Walter C Herlihy||CEO||Sell||40,000||$8.97||$358,800.00|| |
|9/21/2012||Glenn L Md Cooper||Director||Buy||10,000||$6.09||$60,900.00|| |
|8/16/2012||Michael A Griffith||Director||Buy||2,000||$4.88||$9,760.00|| |
Repligen (NASDAQ RGEN) News Headlines
|Repligen Co. (RGEN) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - March 18 at 3:42 AM
| Analysts Anticipate Repligen Co. (RGEN) Will Post Quarterly Sales of $43.88 Million|
www.americanbankingnews.com - March 18 at 1:56 AM
|Will Repligen Corporation’s (NASDAQ:RGEN) Earnings Grow In The Year Ahead?|
finance.yahoo.com - March 16 at 6:37 PM
|Repligen Co. Expected to Earn FY2020 Earnings of $0.98 Per Share (RGEN)|
www.americanbankingnews.com - March 15 at 2:25 PM
|Repligen (RGEN) Upgraded by TheStreet to "B-"|
www.americanbankingnews.com - March 15 at 1:00 PM
|William Blair Weighs in on Repligen Co.'s Q1 2018 Earnings (RGEN)|
www.americanbankingnews.com - March 14 at 7:20 AM
|Repligen Co. (RGEN) Director Sells $169,807.36 in Stock|
www.americanbankingnews.com - March 12 at 7:57 PM
|Repligen (RGEN) Upgraded to "Hold" by BidaskClub|
www.americanbankingnews.com - March 10 at 4:59 PM
|Ranger Investment Management L.P. Sells 33,620 Shares of Repligen Co. (RGEN)|
www.americanbankingnews.com - March 5 at 3:37 PM
|Repligen Co. (RGEN) Holdings Lifted by Wells Fargo & Company MN|
www.americanbankingnews.com - March 5 at 3:10 PM
|State of Wisconsin Investment Board Increases Holdings in Repligen Co. (RGEN)|
www.americanbankingnews.com - March 5 at 1:56 PM
|Mackenzie Financial Corp Grows Holdings in Repligen Co. (RGEN)|
www.americanbankingnews.com - March 3 at 12:56 PM
|Cortina Asset Management LLC Lowers Holdings in Repligen Co. (RGEN)|
www.americanbankingnews.com - March 2 at 12:48 PM
|Sei Investments Co. Has $6.08 Million Holdings in Repligen Co. (RGEN)|
www.americanbankingnews.com - March 2 at 7:08 AM
|Zacks: Analysts Expect Repligen Co. (RGEN) Will Post Quarterly Sales of $44.52 Million|
www.americanbankingnews.com - March 1 at 2:58 AM
| Analysts Expect Repligen Co. (RGEN) to Post $0.16 EPS|
www.americanbankingnews.com - February 27 at 7:08 PM
|Schroder Investment Management Group Has $17.35 Million Position in Repligen Co. (RGEN)|
www.americanbankingnews.com - February 26 at 1:50 PM
|Repligen Co. (RGEN) Holdings Reduced by OppenheimerFunds Inc.|
www.americanbankingnews.com - February 26 at 1:48 PM
|Q3 2018 EPS Estimates for Repligen Co. (RGEN) Reduced by First Analysis|
www.americanbankingnews.com - February 26 at 4:37 AM
|Q1 2018 EPS Estimates for Repligen Co. (RGEN) Cut by Jefferies Group|
www.americanbankingnews.com - February 26 at 2:06 AM
|Repligen Co. (RGEN) Expected to Post Q1 2019 Earnings of $0.20 Per Share|
www.americanbankingnews.com - February 23 at 2:36 PM
|Repligen beats Street 4Q forecasts|
finance.yahoo.com - February 22 at 5:43 PM
|Repligen (RGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS|
www.americanbankingnews.com - February 22 at 11:12 AM
|Repligen (RGEN) Releases FY18 Earnings Guidance|
www.americanbankingnews.com - February 22 at 9:16 AM
|Repligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 2018|
finance.yahoo.com - February 22 at 8:11 AM
|Repligen Co. (RGEN) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - February 21 at 3:52 AM
|Repligen to Report Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - February 16 at 8:10 AM
|Repligen (RGEN) to Release Quarterly Earnings on Thursday|
www.americanbankingnews.com - February 15 at 1:08 AM
|$41.33 Million in Sales Expected for Repligen Co. (RGEN) This Quarter|
www.americanbankingnews.com - February 13 at 6:52 AM
|Repligen Co. (RGEN) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - January 27 at 4:14 AM
| Analysts Expect Repligen Co. (RGEN) to Announce $0.12 Earnings Per Share|
www.americanbankingnews.com - January 25 at 5:12 AM
|Insider Selling: Repligen Co. (RGEN) CEO Sells 8,970 Shares of Stock|
www.americanbankingnews.com - January 24 at 6:50 PM
|Repligen (RGEN) Cut to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 24 at 11:46 AM
|Repligen (RGEN) Downgraded to Sell at BidaskClub|
www.americanbankingnews.com - January 21 at 1:34 PM
|Zacks: Brokerages Anticipate Repligen Co. (RGEN) to Post $0.12 Earnings Per Share|
www.americanbankingnews.com - January 8 at 1:30 AM
|Repligen Co. (RGEN) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - January 2 at 4:22 AM
|Repligen (RGEN) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - December 30 at 1:26 PM
|Repligen To Present at 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - December 30 at 7:50 AM
|Repligen To Present at 36th Annual J.P. Morgan Healthcare Conference|
finance.yahoo.com - December 29 at 3:21 PM
|ETFs with exposure to Repligen Corp. : December 29, 2017|
finance.yahoo.com - December 29 at 3:21 PM
|Repligen Corp. :RGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017|
finance.yahoo.com - December 28 at 5:02 PM
|3 Growth Stocks to Buy for 2018|
finance.yahoo.com - December 20 at 7:12 AM
|Repligen Corp. – Value Analysis (NASDAQ:RGEN) : December 19, 2017|
finance.yahoo.com - December 19 at 3:22 PM
|Insider Selling: Repligen Co. (RGEN) VP Sells 12,729 Shares of Stock|
www.americanbankingnews.com - December 18 at 9:04 PM
|Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : December 18, 2017|
finance.yahoo.com - December 18 at 3:22 PM
|Why Repligen Corporation’s (NASDAQ:RGEN) ROE Of 5.70% Does Not Tell The Whole Story|
finance.yahoo.com - December 14 at 7:22 AM
|Repligen (RGEN) Coverage Initiated by Analysts at Citigroup|
www.americanbankingnews.com - December 8 at 10:28 PM
| Analysts Expect Repligen Co. (RGEN) Will Post Quarterly Sales of $41.37 Million|
www.americanbankingnews.com - December 6 at 2:18 AM
|Repligen (RGEN) Earns Overweight Rating from Analysts at J P Morgan Chase & Co|
www.americanbankingnews.com - December 5 at 5:12 PM
|JPMorgan Starts Repligen (RGEN) at Overweight, "The Best Pure Play" - StreetInsider.com|
www.streetinsider.com - December 5 at 7:10 AM
Repligen (NASDAQ:RGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Repligen (NASDAQ:RGEN) Income Statement, Balance Sheet and Cash Flow Statement
Repligen (NASDAQ RGEN) Stock Chart for Wednesday, March, 21, 2018